People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cidara Therapeutics, Inc. | — | Biotechnology | Series D+ | $349.1M | $2.8B | 2015 |
| Cortexyme, Inc. | — | Pharmaceuticals | Series C | $111.5M | $71.9M | 2025 |
| Geom Therapeutics, Inc. | — | Biotechnology | Series A | $4.4M | $157.4M | 2017 |
Dirk Thye at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dirk Thye on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Heron | 1 | 11 |
| Nina Kjellson | 1 | 11 |
| SCOTT ROCKLAGE | 1 | 9 |
| Ilan Zipkin | 1 | 6 |
| Dov Goldstein | 1 | 6 |
| Theodore R. Schroeder | 1 | 4 |
| Scott M. Rocklage | 1 | 4 |
| Steve Elms | 1 | 4 |
| Casey Lynch | 1 | 4 |
| Jeffrey Stein | 1 | 4 |
| Una Ryan | 1 | 4 |
| COOPER COLLINS | 1 | 3 |
| Kevin Judice | 1 | 3 |
| Kevin Forrest | 1 | 3 |
| Daniel D. Burgess | 1 | 3 |
| Charles Ryan | 1 | 3 |
| Timothy R. Franson | 1 | 2 |
| Margi McLoughlin | 1 | 2 |
| Roger Quy | 1 | 2 |
| Ken Bartizal | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.